February 22, 2019 – Toronto – The following is a statement by Jim Keon, Chair of the International Generic and Biosimilars medicines Association (IGBA), on the passing of Dilip Shah, Secretary-General of the Indian Pharmaceutical Association (IPA).
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the association. Her main role is to coordinate the IGBA activities as IGBA continues to expand its outreach relevant to its mission, priorities and operations.
The International Generic and Biosimilar Medicines Association (IGBA) strengthens cooperation between associations who represent manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. IGBA’s full-members include the Canadian Generic Pharmaceutical Association, Medicines for Europe, the Association for Accessible Medicines (USA), Japan Generic Medicines Association, Jordanian Association of Pharmaceutical Manufacturers, Indian Pharmaceutical Alliance, Generic & Biosimilar Medicines Southern Africa, and Taiwan Generic Pharmaceutical Association.
- IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applications
- IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures
- IGBA submission to HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49]
- Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest